Home › Funds › RA CAPITAL MANAGEMENT, L.P. › RYTM

RA CAPITAL MANAGEMENT, L.P. position in RYTM

RHYTHM PHARMACEUTICALS INC · Health Care

RA CAPITAL MANAGEMENT, L.P. reported holding 6,666,837 shares of RYTM (RHYTHM PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$740.2M, representing 6.43% of its reported portfolio and ranking #3 among its reported holdings. RA CAPITAL MANAGEMENT, L.P. has disclosed RYTM holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)6.67M sh
Reported value held$740.22M
Portfolio Weight6.43%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How RA CAPITAL MANAGEMENT, L.P.'s RYTM position evolved

RA CAPITAL MANAGEMENT, L.P. first disclosed a stake in RYTM in Q3 2023 at 5,676,067 shares (US$130.1M). The position peaked in Q2 2026 at 6,666,837 shares, worth US$740.2M. Across 12 filings, RA CAPITAL MANAGEMENT, L.P. increased the stake 3 time(s), trimmed it 2 time(s) and left it unchanged 6 time(s). The most recent filing (Q2 2026) shows 6,666,837 shares valued at US$740.2M.

Quarter by quarter

QuarterSharesValueChange
Q3 2023 5.68M $130.12M New
Q4 2023 5.33M $245.04M Reduce
Q1 2024 5.33M $230.97M Hold
Q2 2024 6.08M $249.83M Add
Q3 2024 6.08M $318.76M Hold
Q4 2024 6.08M $340.61M Hold
Q1 2025 6.08M $322.29M Hold
Q2 2025 5.56M $351.42M Reduce
Q3 2025 5.68M $573.76M Add
Q4 2025 6.67M $713.62M Add
Q1 2026 6.67M $579.81M Hold
Q2 2026 6.67M $740.22M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RYTM and 13F data

RYTM (RHYTHM PHARMACEUTICALS INC) is a Health Care company. 51 other funds we track also report a position in RYTM — the largest reported positions include BAKER BROS. ADVISORS LP (US$622.3M), PERCEPTIVE ADVISORS LLC (US$287.2M), WESTFIELD CAPITAL MANAGEMENT CO LP (US$245.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RYTM

All RYTM fund holders →

FAQ

How long has RA CAPITAL MANAGEMENT, L.P. held RYTM?

RA CAPITAL MANAGEMENT, L.P. has disclosed RYTM holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is RA CAPITAL MANAGEMENT, L.P.'s current position in RYTM?

As of Q2 2026, RA CAPITAL MANAGEMENT, L.P. holds 6.67M shares of RYTM (RHYTHM PHARMACEUTICALS INC), valued at $740.22M, representing 6.43% of its reported portfolio and ranking #3.

Has RA CAPITAL MANAGEMENT, L.P. been buying or selling RYTM?

In the latest 13F filing (Q2 2026), RA CAPITAL MANAGEMENT, L.P. held unchanged its position in RYTM. The position peaked in Q2 2026 at 6.67M shares.

Which other funds hold RYTM?

Other major institutional holders of RYTM include BAKER BROS. ADVISORS LP, PERCEPTIVE ADVISORS LLC, WESTFIELD CAPITAL MANAGEMENT CO LP, among 51 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.